San Francisco startup Composition Therapeutics can be working on an oral, the moment-day by day GLP-1 drug identified as GSBR-1290—the drug surpassed Wall Street’s anticipations in June each time a mid-stage review confirmed regular weight loss of about 6% and it plans to start A different mid-stage demo toward the tip of the year—that founde